Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: J Surg Res. 2013 May 11;184(1):10.1016/j.jss.2013.04.042. doi: 10.1016/j.jss.2013.04.042

Fig. 5.

Fig. 5

pCR following neoadjuvant chemotherapy is associated with high TFAP2C and low CD44 expression. Data points represent patients graphed according to TFAP2C and CD44 positivity on immunohistochemistry. Patients with high TFAP2C (≥80%) and low CD44 (≤80%) were significantly more likely to achieve a pCR (57%) compared with all other expression patterns (0%, P = 0.004).